Whitepaper: Early product characterisation mitigates risks in biologics development
Posted: 4 March 2021 | Merck | No comments yet
Product characterisation facilitates easier process design to ensure the biological drug attains critical product safety, purity, and potency.
Product characterisation is the essential foundation for successful biological drug development. In-depth knowledge of a product’s chemistry, structure, and biological activities facilitates easier process design to ensure the drug attains critical product safety, purity, and potency. Key is understanding the relationship between the basic physicochemical profile and biological activity and how this relationship affects clinical performance thus enabling a developer to make informed decisions that accelerate development and reduce risk throughout the product’s life cycle.
Related content from this organisation
- Formulation development outsourcing market to be worth over $60bn by 2030
- Pursuing new paths in targeted protein degradation drug development
- Efficient shutdown recovery: leveraging RMM to unlock value and ensure environmental quality
- Improved outcome for prostate cancer patients in Phase III PROpel trial
- Testing non-inferiority for accuracy of quantitative microbiological methods
Related topics
Biologics, Biopharmaceuticals, Bioprocessing, Biosimilars, Chromatography, Endotoxin, Gene therapy, Good Manufacturing Practice (GMP), Ingredients, Manufacturing, Mass Spectrometry, Outsourcing, QA/QC, Regulation & Legislation, Research & Development (R&D), Vaccines
